ACADIA Pharmaceuticals Current Ratio 2006-2021 | ACAD

ACADIA Pharmaceuticals current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
ACADIA Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.65B $0.10B 6.77
2021-03-31 $0.67B $0.11B 6.16
2020-12-31 $0.72B $0.11B 6.77
2020-09-30 $0.73B $0.09B 7.95
2020-06-30 $0.74B $0.09B 8.51
2020-03-31 $0.72B $0.10B 7.26
2019-12-31 $0.76B $0.08B 10.16
2019-09-30 $0.74B $0.07B 10.96
2019-06-30 $0.44B $0.06B 6.85
2019-03-31 $0.48B $0.08B 6.35
2018-12-31 $0.53B $0.06B 8.83
2018-09-30 $0.25B $0.04B 6.08
2018-06-30 $0.30B $0.05B 6.12
2018-03-31 $0.34B $0.05B 7.38
2017-12-31 $0.37B $0.05B 7.62
2017-09-30 $0.40B $0.04B 11.12
2017-06-30 $0.44B $0.04B 10.85
2017-03-31 $0.49B $0.05B 10.82
2016-12-31 $0.55B $0.04B 12.87
2016-09-30 $0.60B $0.04B 15.42
2016-06-30 $0.42B $0.03B 14.61
2016-03-31 $0.46B $0.02B 21.89
2015-12-31 $0.22B $0.02B 10.00
2015-09-30 $0.24B $0.02B 13.69
2015-06-30 $0.27B $0.02B 14.11
2015-03-31 $0.30B $0.02B 18.01
2014-12-31 $0.33B $0.02B 20.50
2014-09-30 $0.34B $0.01B 30.31
2014-06-30 $0.36B $0.01B 38.43
2014-03-31 $0.37B $0.01B 46.41
2013-12-31 $0.19B $0.01B 26.99
2013-09-30 $0.20B $0.01B 25.25
2013-06-30 $0.21B $0.01B 26.59
2013-03-31 $0.10B $0.01B 18.08
2012-12-31 $0.11B $0.01B 18.25
2012-09-30 $0.02B $0.01B 3.89
2012-06-30 $0.02B $0.01B 3.22
2012-03-31 $0.03B $0.01B 4.10
2011-12-31 $0.03B $0.01B 5.18
2011-09-30 $0.04B $0.01B 5.74
2011-06-30 $0.04B $0.01B 6.90
2011-03-31 $0.05B $0.01B 7.58
2010-12-31 $0.04B $0.01B 6.35
2010-09-30 $0.04B $0.01B 2.66
2010-06-30 $0.04B $0.01B 2.95
2010-03-31 $0.04B $0.01B 3.12
2009-12-31 $0.05B $0.02B 3.30
2009-09-30 $0.06B $0.02B 3.73
2009-06-30 $0.07B $0.02B 3.26
2009-03-31 $0.05B $0.01B 4.22
2008-12-31 $0.06B $0.01B 5.65
2008-09-30 $0.08B $0.01B 6.74
2008-06-30 $0.09B $0.01B 6.70
2008-03-31 $0.11B $0.01B 8.18
2007-12-31 $0.13B $0.02B 6.81
2007-09-30 $0.15B $0.02B 8.45
2007-06-30 $0.16B $0.01B 10.95
2007-03-31 $0.07B $0.02B 4.19
2006-12-31 $0.09B $0.02B 4.18
2006-09-30 $0.10B $0.02B 4.71
2006-06-30 $0.11B $0.03B 4.45
2006-03-31 $0.06B $0.02B 2.81
2005-12-31 $0.06B $0.02B 2.77
2005-09-30 $0.07B $0.02B 3.45
2005-06-30 $0.07B $0.01B 6.45
2005-03-31 $0.04B $0.01B 3.73
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.821B $0.442B
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86